Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Rang in Aktien
#3418
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Aktienkurs
$4.48
Marktkapitalisierung
$4.99B
Veränderung (1 Tag)
-5.20%
Veränderung (1 Jahr)
-41.89%
Land
CN
Handel Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Kategorie
Healthcare
Gewinn für Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Gewinn im Jun 2026 TTM: $95.41M
Laut den aktuellen Finanzberichten von Shenzhen Salubris Pharmaceuticals Co., Ltd. betragen die aktuellen Gewinne des Unternehmens $95.41M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $86.66M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2023, der $90.66M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Shenzhen Salubris Pharmaceuticals Co., Ltd. von 2006 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $95.41M | 1.77% |
| 2025 | $93.75M | 8.18% |
| 2024 | $86.66M | -4.42% |
| 2023 | $90.66M | -12.38% |
| 2022 | $103.47M | 9.64% |
| 2021 | $94.38M | 986.53% |
| 2020 | $8.69M | -92.90% |
| 2019 | $122.26M | -50.71% |
| 2018 | $248.05M | -5.91% |
| 2017 | $263.64M | 10.90% |
| 2016 | $237.72M | 3.50% |
| 2015 | $229.68M | 16.86% |
| 2014 | $196.54M | 22.09% |
| 2013 | $160.97M | 33.79% |
| 2012 | $120.32M | 59.83% |
| 2011 | $75.28M | 19.59% |
| 2010 | $62.95M | 72.35% |
| 2009 | $36.52M | 96.81% |
| 2008 | $18.56M | 76.92% |
| 2007 | $10.49M | 123.31% |
| 2006 | $4.70M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $3.62B | 3,693.17% |
US
|
|
| $4.11B | 4,206.59% |
FR
|
|
| $2.19B | 2,197.71% |
JP
|
|
| $1.59B | 1,566.52% |
US
|
|
| - | - |
CH
|
